Specialised Therapeutics Acquires Commercialisation Rights for New Motor Neuron Disease Therapy

Specialised Therapeutics has recently announced a collaboration with Treeway to bring a new therapy TW001 to Australia and New Zealand for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the most common form of Motor Neurone Disease (MND).

Under the terms of agreement, Specialised Therapeutics takes charge of various aspects such as marketing, regulatory processes, and distribution of TW001 for ALS/MND in Australia and New Zealand.

TW001, the innovative therapy, is an oral formulation of edaravone. Its mechanism of action involves reducing the oxidative damage that contributes to the death of neurons in ALS. Currently, TW001 is undergoing evaluation in a crucial phase III clinical trial called ADORE, being conducted at nearly 40 global sites.

Amyotrophic Lateral Sclerosis (ALS) is a prevalent motor neuron disease marked by the progressive degeneration of motor neurons in the spinal cord and brain. This degeneration leads to gradual paralysis, often resulting in death within 2 to 5 years after diagnosis.

ALS is relatively rare disease affecting individuals aged between 40 to 70, with slightly more cases occurring in men than in women. While 10-15 percent of cases have a genetic or familial link, the remaining 85-90 percent are classified as sporadic cases, where the exact cause is not yet known.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!